Where qualifying R&D is most prevalent.
Qualification is assessed project by project. The sector provides technical context — not a predetermined outcome.
Pharmaceuticals
Drug development, novel formulations, bioequivalence studies, clinical trial design, compound research. Our primary sector focus from inception.
Technology & Software
Novel architectures, AI/ML model development, algorithm innovation — where genuine technical uncertainty exists in the approach, not just the market.
Manufacturing
Process innovation, advanced materials, new product development. R&D in manufacturing is often embedded within production and requires direct operational understanding to identify.
Energy & CleanTech
Renewable energy, storage and conversion systems, grid integration, and environmental engineering. Significant qualifying activity across the energy transition.
Engineering
Structural innovation, advanced materials science, novel construction methodologies with genuine experimental uncertainty.
Life Sciences & Biotech
Medical devices, diagnostics, genomics, bioinformatics. Often technically complex and well-documented — suited to structured claim preparation.
The narrative is sector-specific by design.
A pharmaceutical claim and a software claim require fundamentally different technical narratives. OAM Advisory engagements draw on technical expertise matched to the client's sector — this affects how projects are scoped, how technical uncertainty is characterised, and how the claim holds up under scrutiny.
Eligibility is confirmed per project, not per sector.
The free assessment examines each candidate project individually.